1 of 1
Story summary
- Kalshi also plans bets on drug trial outcomes.
- Researchers and former FDA commissioner Dr. Robert Califf say the markets could compromise study results, enable insider trading, and erode trust.
- A Change.org petition with 180 signatures urges regulators to act while HHS spokeswoman Emily Hilliard notes agency employees have ethics requirements.
